FDA Peptide Tracker

Gonadorelin: live FDA regulatory status

Hormone-support peptide · Hormone

The two signals

Plain-English verdict: amber.

Regulatory status: 503A interim Category 1 (enforcement discretion, not the 503A Bulks List).

These two never collapse into one. Removal from a list is not the same as legal-to-compound, and neither is the same as available.

Availability at Peptós.LIFE

Join waitlist

What happens next

Compoundable now — Current

Regulatory timeline

• Long-standing approved hormone agent
• 2026 — 503A interim Category 1 — enforcement discretion, not the Bulks List

Gonadorelin: common questions

Is Gonadorelin legal in 2026?

Yes. Gonadorelin is in FDA's interim Category 1 — enforcement discretion, not the 503A Bulks List, which is a notice-and-comment rulemaking codified at 21 CFR 216.23 and contains six substances, none of them a peptide. In practice a licensed pharmacy can compound it for an individual patient on a valid prescription. FDA has also said it does not intend to place bulk drug substances nominated on or after January 7, 2025 into these categories, so the interim framework is being wound down. Compounded medications are prepared for an individual patient and are not FDA-approved.

Can I get Gonadorelin right now?

Yes, if a clinician decides it is appropriate for you. A US-licensed clinician of record reviews your health information online and prescribes only when clinically appropriate — there is no way to buy it without that review.

Is Gonadorelin FDA-approved?

The compounded form is not. Compounding under 503A is a legal pathway, not an approval: compounded preparations are not evaluated or approved by the FDA for safety, efficacy, or quality. We say that plainly wherever we name one.

What happens next for Gonadorelin?

Nothing pending. Gonadorelin is compoundable now and we are not aware of a scheduled FDA action that would change that. This page carries the date it was last reviewed.

PCAC is advisory: its Jul 2026 recommendation leads to rulemaking, not instant availability. A favorable advisory vote is a recommendation, not FDA approval or authorization to compound. Realistic earliest legitimate access is late 2026 into 2027. Reclassification is not the same as FDA approval. Compounded medications are not evaluated or approved by the FDA for safety, efficacy, or quality, where that applies, we say so, plainly.

Primary source: FDA source record

See the full status board or this molecule's knowledge-base monograph.

Embed this card on your site · free, CC BY 4.0, no key.

Last updated July 26, 2026 · Peptós.LIFE · Not medical advice.